The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01455441
Recruitment Status : Completed
First Posted : October 20, 2011
Last Update Posted : May 29, 2015
Information provided by (Responsible Party):
Tina Vilsboll, University Hospital, Gentofte, Copenhagen

October 19, 2011
October 20, 2011
May 29, 2015
October 2011
June 2013   (Final data collection date for primary outcome measure)
HbA1c [ Time Frame: 16 weeks ]
Change in HbA1c from baseline to 16 weeks. Glycated haemoglobin (HbA1c) is a form of haemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time (12 weeks).
Same as current
Complete list of historical versions of study NCT01455441 on Archive Site
  • Maximal oxygen uptake (VO2peak) [ Time Frame: 16 weeks ]
    Changes in VO2peak from baseline to 16 weeks
  • Body weight [ Time Frame: 16 weeks ]
    Changes in body weight from baseline to 16 weeks evaluated by a full body DEXA scan
  • Blood pressure [ Time Frame: 16 weeks ]
    Changes in blood pressure from baseline to 16 weeks
  • Glycaemic control [ Time Frame: 16 weeks ]
    Changes in overall glycaemic control parameters, insulin sensitivity and beta cell function evaluated by The Homeostasis Model Assessment (HOMA) and incretin hormones response
  • Meal test [ Time Frame: 16 weeks ]
    The changes in the postprandial response of incretin hormones, insulin and glucose, glucagon and the microvascular blood flow will be evaluated. Changes in blood leves of triglycerides and cholesterol.
  • Myocardial echocardiography [ Time Frame: 16 weeks ]
Same as current
Not Provided
Not Provided
The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes
Does the GLP-1 Receptor Agonist (Victoza®) Improve the Metabolic Response to Physical Training in Patients With Type 2 Diabetes?

The objective of this study is to investigate the effects of physical training in patients with type 2 diabetes during treatment with the GLP-1 receptor agonist liraglutide (Victoza®) in a 16-weeks double-blinded, randomized placebo-controlled clinical trial.

Hypothesis: Physical training leads to better metabolic control in type 2 diabetic patients when training is combined with liraglutide (Victoza®) treatment.

Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Type 2 Diabetes
  • Other: Training and liraglutide
  • Other: Training and placebo
  • Active Comparator: Training and liraglutide
    Treatment with both training and liraglutide for 16 weeks
    Intervention: Other: Training and liraglutide
  • Placebo Comparator: Training and placebo
    Treatment wiht both training and placebo for 16 weeks
    Intervention: Other: Training and placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2014
June 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Informed oral and written consent
  • Diagnosed with type 2 diabetes according to the criteria of the WHO
  • HbA1C: 7-11% (doing treatment with diet and/or metformin)
  • Age >18 years
  • BMI >25 kg/m2 <40 kg/m2
  • Negative islet cell antibodies (ICA) and glutamate decarboxylase 65 (GAD- 65) autoantibodies

Exclusion Criteria:

  • Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures.
  • Subjects treated with sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors, insulin or glitazones
  • Ongoing abuse of alcohol or narcotics
  • Impaired hepatic function (liver transaminases >2 times upper normal limit)
  • Impaired renal function (se-creatinine >150μM and/or albuminuria)
  • Cardiac problems defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris and/or myocardial infarction within the last 12 months
  • Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >100 mmHg)
  • Anaemia
  • Any condition that the investigators feels would interfere with trial participation
  • Receiving any investigational drug within the last 3 months
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
60 - TrainIncretin
Not Provided
Not Provided
Tina Vilsboll, University Hospital, Gentofte, Copenhagen
Tina Vilsboll
Not Provided
Not Provided
University Hospital, Gentofte, Copenhagen
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP